Among the macrolide antibiotics, which is the most common cause of drug-drug interactions due to cytochrome P450 enzyme inhibition?

Explanation

## Macrolide-Mediated CYP450 Inhibition **Key Point:** Erythromycin is the most potent CYP3A4 inhibitor among macrolides, making it the most common cause of clinically significant drug-drug interactions. ### Mechanism of CYP450 Inhibition Macrolides inhibit hepatic cytochrome P450 enzymes, particularly CYP3A4, leading to increased plasma concentrations of co-administered drugs metabolized by these pathways. ### Comparative CYP450 Inhibition Profile | Macrolide | CYP3A4 Inhibition | Clinical Significance | Common Interactions | |-----------|-------------------|----------------------|---------------------| | **Erythromycin** | **Strong** | **High** | Theophylline, warfarin, carbamazepine, statins | | Roxithromycin | Moderate | Moderate | Similar to erythromycin but less frequent | | Azithromycin | Weak/Minimal | Low | Rare clinically significant interactions | | Spiramycin | Weak | Low | Minimal interactions | **High-Yield:** Erythromycin inhibits CYP3A4 by forming a stable complex with the heme iron of the enzyme, preventing substrate metabolism. ### Clinical Consequences 1. **Increased drug levels** → toxicity risk 2. **Theophylline toxicity** → arrhythmias, seizures 3. **Warfarin potentiation** → bleeding risk 4. **Statin toxicity** → myopathy, rhabdomyolysis 5. **Carbamazepine levels** → reduced seizure control **Clinical Pearl:** Azithromycin is preferred in patients on multiple medications due to its minimal CYP450 inhibition, making it a safer choice in polypharmacy settings. **Tip:** In NEET PG exams, when asked about macrolide drug interactions, erythromycin is the expected answer — it's the "classic" CYP3A4 inhibitor among this class.